A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Eligibility Criteria

• * Patients must be ≥ 18 years of age
• * Patients must have measurable disease per disease-specific response criteria
• * Patients with indolent forms of NHL must meet the criteria requiring systemic treatment (i.e., iwCLL, IWG, Lugano Classification of Lymphoma response criteria, or International PCNSL Collaborative Group response criteria)
• * Patients with transformed lymphoma are eligible for the study with the exception of those detailed in Exclusion Criteria #1: Prolymphocytic leukemia, MCL with blastoid histology, MCL with pleomorphic morphology, or MCL with known TP53 mutation
• * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (non-PCNSL indications) or 0 - 2 (PCNSL patients)
• * Adequate organ and bone marrow function
• * Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol
• * Have histologically confirmed R/R CLL, SLL, WM, MCL, and MZL, FL, DLBCL, or PCNSL
• * Received at least 2 prior systemic therapies (or at least 1 prior therapy for patients with WM or PCNSL) and have no other therapies known to provide clinical benefit
• * Must require systemic therapy
• * Must have one of the following histologically documented R/R B-cell malignancies:
• * CLL/SLL whose disease has failed treatment with a BTKi;
• * MCL whose disease has failed treatment with BTKi and an anti-CD20 mAb-based regimen
• * FL or MZL whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTKi
• * PCNSL whose disease failed at least 1 prior line of treatment
• * DLBCL whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen, or another/ palliative regimen (either progressed post stem cell transplant or transplant-ineligible)
• * Active, uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia
• * History of known/suspected other autoimmune disease (exception(s): patients with alopecia, vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at screening are allowed.)
• * Unable to swallow capsules or have a condition that may interfere in the delivery, absorption, or metabolism of the study drug
• * Bleeding diathesis, or other known risk for acute blood loss
• * Patients requiring ongoing treatment with warfarin or an equivalent vitamin K antagonist and within 7 days prior to the first dose of study drug
• * Prior radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation)
• * Toxicities from previous anticancer therapies must have resolved to baseline levels or to Grade 1 (except for alopecia, hypothyroidism with adequate replacement therapy, hypopituitarism with adequate replacement therapy, peripheral neuropathy or hematologic parameters meeting inclusion criteria).
• * Active known second malignancy. Exception: patients with non-metastatic, non-melanoma skin cancer are eligible
• * Patient has had major surgery (e.g. requiring general anesthesia) within 4 weeks before the planned first dose of study drug
• * Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: patients with well-controlled HIV (e.g., CD4 \> 350/mm3 and undetectable viral load) are eligible.
• * Current active liver disease from any cause
• * Active viral reactivation (e.g., CMV or EBV)
• * Use of systemic corticosteroids exceeding 20 mg/day prednisone (or equivalent) for non-PCNSL indications within 15 days prior to the planned start of study drug. PCNSL patients may not exceed corticosteroid doses of 40 mg/day prednisone (or equivalent) and should be on a stable or decreasing dose for 7 days prior to planned study start.
• * Use of non-steroidal immunosuppressive drugs within 30 days prior to start of the study
• * Clinically significant, uncontrolled cardiac, cardiovascular disease, or history of myocardial infarction within 6 months of planned start of study drug
• * Administration of any strong cytochrome P450 3A (CYP3A) inducers or inhibitors for 14 days prior to the first dose of study drug, and any P-glycoprotein inhibitors (for 2 days) or moderate inducers of CYP3A for 7 days